Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Genfit S.A. (GNFT)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
3.7100+0.3000 (+8.80%)
At close: 03:59PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close3.6000
Open3.5550
Bid3.1000 x 1000
Ask4.3900 x 1200
Day's Range3.4400 - 3.7100
52 Week Range3.0100 - 6.3800
Volume8,985
Avg. Volume18,322
Market Cap184.486M
Beta (5Y Monthly)1.24
PE Ratio (TTM)N/A
EPS (TTM)-1.0810
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    GENFIT: May 25, 2022 Combined Shareholders Meeting results

    Quorum of 25.16% on first convening; allowing approval of all the resolutions submitted by the Board of Directors Lille, France; Cambridge, MA; May 25, 2022 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with severe chronic liver diseases, today announced the results of the Combined Shareholders Meeting which took place on May 25, 2022. The quorum on first convening amounted to 25.16% and shareholders approved all of the

  • GlobeNewswire

    GENFIT Reports First Quarter 2022 Financial Information (Unaudited financial information under IFRS)

    Cash and cash equivalents totaled €222.2 million as of March 31, 2022 Lille, France; Cambridge, MA; May 11, 2022 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with severe chronic liver diseases, today announced its cash position as of March 31, 2022 and revenues for the first three months of 2022.Cash position As of March 31, 2022, the Company’s cash and cash equivalents amounted to €222.2 million compared with €108.9 mi

  • GlobeNewswire

    GENFIT Announces Publication of the 2021 Universal Registration Document; the 2021 Annual Report on Form 20-F and Availability of Preparatory Documents for the Annual Combined Shareholders Meeting on May 25, 2022

    Lille, France; Cambridge, MA; April 29, 2022 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with severe chronic liver diseases, today announced the filing of its 2021 Universal Registration Document with the Autorité des marchés financiers (AMF) and its Annual Report on Form 20-F for the year ended December 31, 2021 with the U.S. Securities and Exchange Commission (SEC), as well as the availability of preparatory document

Advertisement
Advertisement